Localizing small nodules: Is it time for a randomized trial?

Nasser Altorki, MD, and Eugene Shostak, MD

The near ubiquitous use of computed tomography (CT) resulted in the identification of a substantial number of individuals harboring small pulmonary nodules. Fortunately, the overwhelming majority of these nodules have no clinical consequence. However, in a significant minority of people, particularly those in an acknowledged high-risk group, further workup, which may include thoracic surgical evaluation, is unavoidable. The diagnostic challenge posed by these small, barely visible, or palpable solid and nonsolid nodules has given rise to the appealing concept of nodule localization. There are several reported methods of nodule localization, including CT-guided (hook wire/micro-coil/Lipiodol [Guerbet, Princeton, NJ]), radionuclide-guided, and endoscopic-guided techniques. In the current issue of the *Journal*, Abbas and colleagues’ report on the use of intraoperative electromagnetic navigational bronchoscopic localization (ENB) for the purpose of nodule localization. Approximately half of 54 nodules were ground glass with a mean diameter of 13.9 mm. Their technique involved the transbronchial, often combined delivery of methylene blue, indocyanine green, and Isovue (Bracco, Monroe Township, NJ). After localization, patients underwent immediate surgical resection mainly by sublobar robotic techniques.

The authors successfully localized 98% of patients but at the expense of higher, yet manageable, rates of pneumothoraces, pulmonary bleeding, and wire dislodgments or migration. The question thus remains: Which of the 2 modalities should we preferentially adopt? This is precisely the question that begs a randomized comparison in pursuit of an evidence-based answer. First, it is our opinion that legitimate equipoise exists between the 2 approaches. Second, the primary end point for a potential randomized trial is well defined and immediately discernible, rendering such a trial “easy” to accomplish and well within the purview of our specialty. A such a trial should enroll patients with peripheral nodules that are clearly within size ranges and consistencies universally acknowledged to be neither visible nor palpable. It also should exclude patients harboring nodules located within small pulmonary segments that can be easily excised with diagnostic and potential therapeutic intent. The work by Abbas and others is a good example of how thoracic surgeons can adopt and adapt endoscopic techniques to advance our specialty and benefit our patients. Now it is time to move the field a bit forward.

Central Message

Despite the successful localization of small nodules by bronchoscopic or percutaneous techniques, it is time to perform a comparative trial that determines the optimal localization strategy.

See Article page 1581.

Reference